Novo Nordisk released full results from a late-stage trial showing its Wegovy injection helped children ages 6 to under 12 with obesity lower their body mass index. The company said the results were released on Monday.
Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks. BMI fell 17.4% among children receiving the drug and rose 2.2% among those receiving a placebo. These results assumed patients stayed on treatment.
Across all children in the study, including those who stopped treatment, Wegovy lowered BMI by an estimated average of 16.2 percentage points more than the placebo at 68 weeks. All 167 children received lifestyle changes, including a reduced-calorie diet and increased physical activity.
Novo said 85% of the children started with moderate to severe obesity, and nearly half already had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea. More than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks, assuming they stayed on treatment. Novo first shared that result in September.
Wegovy is already approved for obesity in children ages 12 and older. No medications are currently approved for children under 12. Novo said Wegovy's safety and tolerability in children were consistent with those seen in trials with adults, and that it observed no safety concerns related to growth or pubertal development.
Dr. Andrea Traina, Novo's medical director lead of obesity, said, "This is a very significant disease burden in this very young patient population." She said the two-year study does not establish whether earlier treatment changes the long-term course of the disease, calling that "still an evidence gap."